Ultragenyx Pharmaceutical $RARE

Health Care · NASDAQ

$16.48
-0.74 (-4.30%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Aug 28, 2026, the first target we tracked for RARE.

Ultragenyx Pharmaceutical (RARE) is trading down at $16.48 (-4.30%) on NASDAQ, as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Analyst price targets on RARE

Current price targets from 2 firms average $50 — 203% above the current $16.5. Each is tracked to its date and scored the same way a member's call is.

2 targets, newest first. Open a row for its source and scoring.

DateAug 28, 2026 FirmWells Fargo RatingOverweight · raises Targetat $25.6 · $50 +95% Horizonby Aug 2027 StatusOpen

Entry price $25.6, the close nearest Aug 28, 2026, when the target was reported; the target is +95% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Aug 2027.

Scoring Open: judged on the close on Aug 28, 2027.

Source Wells Fargo raises Ultragenyx Pharma price target on phase 3 data Investing.com · Aug 28, 2026 · opens the publisher's site
Wells Fargo raised its price target on Ultragenyx Pharma stock (NASDAQ:RARE) to $50.00 from $46.00
DateAug 28, 2026 FirmH.C. Wainwright RatingBuy · reiterates Targetat $25.6 · $50 +95% Horizonby Aug 2027 StatusOpen

Entry price $25.6, the close nearest Aug 28, 2026, when the target was reported; the target is +95% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Aug 2027.

Scoring Open: judged on the close on Aug 28, 2027.

Source Wells Fargo raises Ultragenyx Pharma price target on phase 3 data Investing.com · Aug 28, 2026 · opens the publisher's site
H.C. Wainwright reiterated its Buy rating with a $50 price target

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Ultragenyx Pharmaceutical revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$673.0M−$17.2M−$707.4MFY2016 revenue: $133.0KFY2016 net income: −$245.9M · Net margin −184867.7%'16FY2017 revenue: $2.61MFY2017 net income: −$302.1M · Net margin −11567.3%'17FY2018 revenue: $51.5MFY2018 net income: −$197.6M · Net margin −383.7%'18FY2019 revenue: $103.7MFY2019 net income: −$402.7M · Net margin −388.3%'19FY2020 revenue: $271.0MFY2020 net income: −$186.6M · Net margin −68.8%'20FY2021 revenue: $351.4MFY2021 net income: −$454.0M · Net margin −129.2%'21FY2022 revenue: $363.3MFY2022 net income: −$707.4M · Net margin −194.7%'22FY2023 revenue: $434.0MFY2023 net income: −$607.0M · Net margin −139.9%'23FY2024 revenue: $560.0MFY2024 net income: −$569.0M · Net margin −101.6%'24FY2025 revenue: $673.0MFY2025 net income: −$575.0M · Net margin −85.4%'25−100%−50%0%50%FY2016 net margin: −184867.7% (off the scale, which stops at −100.0%)FY2017 net margin: −11567.3% (off the scale, which stops at −100.0%)FY2018 net margin: −383.7% (off the scale, which stops at −100.0%)FY2019 net margin: −388.3% (off the scale, which stops at −100.0%)FY2020 net margin: −68.8%FY2021 net margin: −129.2% (off the scale, which stops at −100.0%)FY2022 net margin: −194.7% (off the scale, which stops at −100.0%)FY2023 net margin: −139.9% (off the scale, which stops at −100.0%)FY2024 net margin: −101.6% (off the scale, which stops at −100.0%)FY2025 net margin: −85.4%
Ultragenyx Pharmaceutical annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$133.0K$2.61M$51.5M$103.7M$271.0M$351.4M$363.3M$434.0M$560.0M$673.0M
Growth (year over year)—+1863.9%+1871.5%+101.4%+161.3%+29.7%+3.4%+19.5%+29.0%+20.2%
Gross profit—$2.61M$50.3M———————
Gross margin—100.0%97.8%———————
Operating income−$248.0M−$328.9M−$371.4M−$424.2M−$330.1M−$381.7M−$648.9M−$569.0M−$536.0M−$535.0M
Operating margin−186471.4%−12593.5%−721.2%−409.0%−121.8%−108.6%−178.6%−131.1%−95.7%−79.5%
Net income−$245.9M−$302.1M−$197.6M−$402.7M−$186.6M−$454.0M−$707.4M−$607.0M−$569.0M−$575.0M
Net margin−184867.7%−11567.3%−383.7%−388.3%−68.8%−129.2%−194.7%−139.9%−101.6%−85.4%
EPS (diluted)−$6.21−$7.12−$3.97−$7.12−$3.07−$6.70−$10.12−$8.25−$6.29−$5.83
Balance sheet
Cash and equivalents$161.1M$100.5M$113.4M$433.6M$713.5M$307.6M$132.9M$214.0M$174.0M$421.0M
Total assets$540.6M$490.8M$719.6M$1.14B$1.76B$1.52B$1.55B$1.49B$1.50B$1.53B
Total liabilities$66.7M$107.3M$110.7M$481.7M$605.2M$599.8M$1.19B$1.22B$1.24B$1.60B
Shareholders' equity$474.0M$383.5M$608.9M$653.8M$1.15B$922.6M$352.0M$275.0M$255.0M−$80.0M
Cash flow
Operating cash flow−$161.0M−$253.8M−$290.6M−$345.4M−$132.2M−$338.7M−$380.5M−$475.0M−$414.0M−$466.0M
Capital expenditure$10.2M$2.79M$4.08M$24.8M$43.9M$73.1M$116.1M$44.0M$7.00M$6.00M
Free cash flow−$171.2M−$256.6M−$294.6M−$370.2M−$176.1M−$411.8M−$496.6M−$519.0M−$421.0M−$472.0M

From Ultragenyx Pharmaceutical's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Ultragenyx Pharmaceutical in the news

Nov 22, 2026 The Guardian Theresa May ‘aghast’ at Andy Burnham’s talk about rejoining EU
Nov 21, 2026 The Motley Fool Is USA Rare Earth Stock a Buy Now?

Also mentions USA Rare Earth Inc Class a

Nov 19, 2026 Barchart.com Apple Nears a Rare Long-Term DRAM Supply Deal With Samsung Electronics. What This Means for AAPL Stock.
Nov 18, 2026 CNBC I watched Trump, Xi and Putin gather in China. Here are my top takeaways
Nov 4, 2026 Yahoo Finance General Electric (GE) Stock May Look Reasonable Following Rare Earth Supply News

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

Source: Wikipedia — Ultragenyx

Headquarters
Novato, California From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →